Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Real-world data on belantamab mafodotin show ORR 38.7% (n=24; 1 CR, 10 VGPR, 13 PR); median DOR 10.7 months (95% CI 3.94–not reached); median PFS 4.5 months (95% CI 3.5–5.2); median OS not estimable (95% CI 11.0 months–NE).”
Title: Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe
Authors: Michele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, Michel Delforge, Fernando Escalante, David Kleinman, Hans C. Lee, Ravi Vij, Richard Greil, Thomas Melchardt, Elisabetta Antonioli, Anna Lysen, Leena Camadoo-O’Byrne, Jacopo Bitetti, Tim d’Estrube, Mark Fry, Julie Byrne, Carla Y. Vossen, Sandhya Sapra, Victoria S. Benson, Jorge Mouro, and Malin Hultcrantz.
You can read the Full Article in Haematologica.
You can find more posts featuring Robert Orlowski on OncoDaily.
